Estrogen Treatment in Acromegalic Women
NCT00315107 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2006-05-26
Summary
Oral estrogens may be an effective adjuvant treatment for control of acromegaly in patients with resistance to somatostatin analogs.
Conditions
Interventions
- DRUG
-
Alesse
Sponsors & Collaborators
- collaborator INDUSTRY
-
Université de Montréal
lead OTHER
Principal Investigators
-
Omar Serri, MD · CHUM- Endocrinology
Study Design
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-05-31
- Completion
- 2007-08-31
Countries
- Canada
Study Locations
More Related Trials
-
Growth Retardation In Children With Special Pathological Conditions Or Disease
NCT00163215 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly
NCT00372697 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
NCT00210457 ·Status: COMPLETED ·Phase: PHASE3
-
Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues
NCT02427295 ·Status: UNKNOWN ·Phase: PHASE4
-
Comparison of Two Growth Hormone Dosing Methods in Adults With Growth Hormone Deficiency
NCT00490191 ·Status: COMPLETED ·Phase: PHASE4
-
Canadian Pegvisomant Compassionate Study In Acromegalic Patients
NCT00151437 ·Status: COMPLETED ·Phase: PHASE4
-
Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects
NCT01723748 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly
NCT00225979 ·Status: COMPLETED ·Phase: PHASE3
-
Somatuline Predictive Factors in Acromegaly and NET
NCT01840449 ·Status: COMPLETED
-
Efficacy and Safety of a High Dosage Compared to the Label Dosage of Somatropin in Early Pubertal Stage Children With Growth Hormone Deficiency
NCT00191165 ·Status: COMPLETED ·Phase: PHASE3
-
One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma
NCT01471405 ·Status: COMPLETED
-
Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
NCT00444873 ·Status: COMPLETED ·Phase: PHASE3
-
Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone
NCT01029275 ·Status: COMPLETED ·Phase: NA
-
Surgical Versus Medical Treatment of Acromegaly
NCT01000090 ·Status: COMPLETED
-
Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas
NCT00242541 ·Status: TERMINATED ·Phase: PHASE4
-
Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly
NCT00499993 ·Status: COMPLETED ·Phase: PHASE3
-
Pasireotide LAR and Pegvisomant Study in Acromegaly
NCT02668172 ·Status: UNKNOWN ·Phase: PHASE4
-
Low and Conventional Dose of Somatropin in Growth Hormone Deficient Adult Patients
NCT00570011 ·Status: COMPLETED ·Phase: PHASE3
-
Acromegaly Treatment Quality of Life Study
NCT01732406 ·Status: COMPLETED
-
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
NCT00447499 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly
NCT02685709 ·Status: COMPLETED ·Phase: PHASE3
-
Bioequivalence of Two Products (Norditropin® Versus Nutropin AQ®) in Healthy Adult Volunteers
NCT01512095 ·Status: WITHDRAWN ·Phase: PHASE1
-
Treatment Patterns and Treatment Outcomes for Acromegaly
NCT03043586 ·Status: COMPLETED
-
Somatropin + Leuprorelin vs Somatropin Alone in Pubertal Children With Idiopathic Short Stature
NCT00355030 ·Status: COMPLETED ·Phase: PHASE3
-
Non Interventional Post Marketing Programme in Acromegaly
NCT00747500 ·Status: COMPLETED